TTU 09.832

Pseudomonas aeruginosa focused antiinfectives pipeline (PAFAP)

01/01/2026 to 31/01/2029

The WHO classifies Pseudomonas aeruginosa as a priority 2 pathogen, which defines a high need for new antibiotics. To address this need, we have assembled a consortium of drug discovery experts with natural products chemistry and medicinal chemistry, microbiology, biotechnology, mode of action and pharmacology expertise with both academic and pharmaceutical industry backgrounds. This consortium allows an efficient management of a drug discovery pipeline from hit discovery to preclinical research. The overall goal is the development of P. aeruginosa-active antibiotics (uridylpeptides) and pathoblockers as two highly complementary approaches. Several natural products and synthetic compound classes are suggested for further investigation, optimization and translational development, which address and understand separate mechanisms of action via novel or underexploited targets.